Greenbaum Lab

Introduction

Our group focuses on prediction and prevention of type 1 diabetes (T1D) as well as discovery and validation of biomarkers of disease progression and response to therapy. More than 35 years of this work recently led to the first FDA approved disease modifying therapy to delay the onset of T1D in at risk individuals, setting a precedent for treatment before the clinical appearance of other autoimmune diseases as well.

Our highly collaborative team of clinical and translational investigators, biostatisticians, study coordinators, research nurses and administrative support conducts clinical research and clinical trials. This includes academic multi-center and single site trials as well as investigator initiated and early phase industry sponsored studies. Our clinical research studies include short term interventions with mechanistic outcomes termed EMU or Experimental Medicine Unit studies as well as studies testing novel methods for measures of insulin secretion and immune response. Study participants for clinical research and clinical trials come from the 5 state Pacific Northwest region and are seen for research visits on our Clinical Research Center. 

Carla J Greenbaum
Director, Center for Interventional Immunology

Carla Greenbaum, MD

Director, Center for Interventional Immunology; Member; Affiliate Faculty, University of Washington Medicine
View Full Bio

Research Projects

Greenbaum Research Project Preview - Type 1 Diabetes TrialNet

TrialNet clinical trials in those at risk of type 1 diabetes

We are deeply engaged in TrialNet studies and science, including our ongoing Pathway to Prevention trial that screens family member of T1D patients for T1D risk and the successful Teplizumab Prevention Trial.  
View Project
Greenbaum Research Project Preview - Collaboration with Industry Partners

Collaborations with Industry Partners to test new T1D therapies

The Greenbaum Lab collaborates with industry partners to test new T1D therapeutics, often involving multi-site phase 2 and phase 3 randomized clinical trials with the goal of understanding the efficacy of new therapies.
View Project
Greenbaum Research Project Preview - Experimental Medicine Unit

Experimental Medicine Unit studies at BRI

Dr. Greenbaum works with the Experimental Medicine Unit (EMU) at BRI to understand the biology behind experimental therapies. Most of these studies focus on type 1 diabetes.
View Project
Greenbaum Research Project Preview - Immune Tolerance Network

Immune Tolerance Network (ITN) clinical trials in type 1 diabetes

In collaboration with the Immune Tolerance Network, our group conducts studies to understand the ways T1D therapies promote immune tolerance and to identify biomarkers associated with immune tolerance.
View Project

Lab Members

Anna Barash

Anna Barash, MSN, RN, CDCES

Research Nurse/Diabetes Educator, Center for Interventional Immunology
Emily Batts

Emily Batts

Project Manager, Center for Interventional Immunology
Katie Bennett

Katie Bennett

Outreach Coordinator, Center for Interventional Immunology
Kassidy Benoscek

Kassidy Benoscek

Clinical Research Manager, Center for Interventional Immunology
Natalie Clary

Natalie Clary

Research Assistant, Center for Interventional Immunology
Deric Khuat

Deric Khuat

Clinical Research Coordinator, Center for Interventional Immunology
Rishab Kotak

Rishab Kotak

Research Assistant, Center for Interventional Immunology
David Lee

David Lee

Clinical Research Coordinator, Center for Interventional Immunology
Sandra Lord

Sandra Lord, MD

Clinical Director, Center for Interventional Immunology; Director, Clinical Research Center
View Bio
Courtney Mills

Courtney Mills

Research Assistant, Center for Interventional Immunology
Sunitha Murali

Sunitha Murali

Clinical Research Coordinator, Center for Interventional Immunology
Bao Ng

Bao Ng, DNP, ARNP

Nurse Practitioner, Center for Interventional Immunology
Katelyn Orcino

Katelyn Orcino

Research Assistant, Center for Interventional Immunology
Arielle Pagryzinski

Arielle Pagryzinski

Program Manager, Center for Interventional Immunology
Maia Rabinowitz

Maia Rabinowitz

Research Assistant, Center for Interventional Immunology
Sarah Robinson

Sarah Robinson

Administrative Assistant, Center for Interventional Immunology
Cate Speake

Cate Speake, PhD

Research Assistant Member; Principal Investigator; Scientific Director, Interventional Immunology
View Bio
Jodie Stroeve

Jodie Stroeve

Research Assistant, Center for Interventional Immunology
William Thornton

William Thornton

Research Assistant, Center for Interventional Immunology
Danielle Tom

Danielle Tom

Project Manager, Center for Interventional Immunology
Corinna Tordillos

Corinna Tordillos

Clinical Research Lead, Center for Interventional Immunology
Dana VanBuecken

Dana VanBuecken, ARNP

Nurse Practitioner, Center for Interventional Immunology
Kim Varner

Kim Varner

Administrative Manager, Center for Interventional Immunology
Marlie Wells

Marlie Wells

Research Assistant, Center for Interventional Immunology
Nancy Wickstrom

Nancy Wickstrom

Outreach Supervisor, Center for Interventional Immunology

Related Stories

Blog Main Image - Clinician Woman Talking Patient Man Senior 2
March 14, 2023

Prediction and Prevention: A New Paradigm in Autoimmune Disease

The FDA recently approved teplizumab, a groundbreaking therapy that signals a paradigm shift in treating not only T1D but all autoimmune diseases.
Read Article
Blog Main Image - T1D Diabetes Monitoring Blood Sugar Test
November 17, 2022

Teplizumab FAQ: Your Questions Answered About New Therapy to Delay T1D

Scientists at the Benaroya Research Institute (BRI) and TrialNet, a global type 1 diabetes (T1D) research consortium, have spent decades working to answer a bold question: Can we stop T1D before it starts?

Read Article
Blog Main Image - T1D Diabetes Medical Technology
August 31, 2021

Beyond Insulin: Beyond BRI's Quest to Stop Type 1 Diabetes

The discovery of insulin 100 years ago transformed type 1 diabetes (T1D) from a death sentence to a chronic illness. Yet T1D is still a relentless disease with no cure.

Read Article

News

News Main Image - Puget Sound Business Journal

Benaroya Research Institute’s Dr. Carla Greenbaum Receives Puget Sound Business Journal Lifetime Achievement Award

Read More
Science in Seattle Logo

Science in Seattle: Characterizing T Cell Responses to Enzymatically Modified Beta Cell Neo-Epitopes

Read the publication ➡
Science in Seattle Logo

Science in Seattle: IL-6–targeted therapies to block the cytokine or its receptor drive distinct alterations in T cell function

Read the Publication ➡